A detailed history of Group One Trading, L.P. transactions in Liquidia Corp stock. As of the latest transaction made, Group One Trading, L.P. holds 235,887 shares of LQDA stock, worth $2.51 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
235,887
Previous 129,761 81.79%
Holding current value
$2.51 Million
Previous $1.56 Million 51.45%
% of portfolio
0.1%
Previous 0.05%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$8.9 - $14.11 $944,521 - $1.5 Million
106,126 Added 81.79%
235,887 $2.36 Million
Q2 2024

Aug 14, 2024

BUY
$11.96 - $15.71 $622,613 - $817,831
52,058 Added 67.0%
129,761 $1.56 Million
Q1 2024

May 10, 2024

BUY
$11.35 - $16.73 $803,580 - $1.18 Million
70,800 Added 1025.64%
77,703 $1.15 Million
Q4 2023

Feb 14, 2024

SELL
$5.77 - $12.19 $104,558 - $220,894
-18,121 Reduced 72.41%
6,903 $83,000
Q3 2023

Nov 09, 2023

SELL
$6.27 - $8.15 $144,724 - $188,118
-23,082 Reduced 47.98%
25,024 $158,000
Q2 2023

Aug 09, 2023

BUY
$6.63 - $9.9 $318,942 - $476,249
48,106 New
48,106 $377,000
Q4 2022

Feb 09, 2023

BUY
$4.68 - $6.54 $17,372 - $24,276
3,712 New
3,712 $23,000
Q2 2022

Aug 11, 2022

SELL
$3.37 - $7.55 $55,625 - $124,620
-16,506 Reduced 31.27%
36,282 $158,000
Q1 2022

May 12, 2022

BUY
$5.14 - $7.38 $51,523 - $73,977
10,024 Added 23.44%
52,788 $379,000
Q4 2021

Feb 11, 2022

BUY
$2.71 - $5.17 $72,652 - $138,602
26,809 Added 168.03%
42,764 $208,000
Q3 2021

Nov 12, 2021

SELL
$2.28 - $2.95 $911 - $1,180
-400 Reduced 2.45%
15,955 $44,000
Q2 2021

Aug 10, 2021

SELL
$2.51 - $3.11 $15,765 - $19,533
-6,281 Reduced 27.75%
16,355 $47,000
Q1 2021

May 12, 2021

BUY
$2.42 - $3.6 $54,779 - $81,489
22,636 New
22,636 $61,000

Others Institutions Holding LQDA

About Liquidia Corp


  • Ticker LQDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,362,300
  • Market Cap $685M
  • Description
  • Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...
More about LQDA
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.